Pyxis Oncology, Inc. (PYXS)
3.38
-0.51
(-13.11%)
USD |
NASDAQ |
Sep 09, 16:00
3.38
0.00 (0.00%)
After-Hours: 16:48
Pyxis Oncology Enterprise Value : 230.13M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 230.13M |
| September 04, 2026 | 230.13M |
| September 03, 2026 | 209.51M |
| September 02, 2026 | 221.24M |
| September 01, 2026 | 201.58M |
| August 31, 2026 | 188.89M |
| August 28, 2026 | 188.26M |
| August 27, 2026 | 193.97M |
| August 26, 2026 | 195.24M |
| August 25, 2026 | 177.47M |
| August 24, 2026 | 171.13M |
| August 21, 2026 | 178.74M |
| August 20, 2026 | 181.28M |
| August 19, 2026 | 197.14M |
| August 18, 2026 | 173.03M |
| August 17, 2026 | 174.94M |
| August 14, 2026 | 174.30M |
| August 13, 2026 | 174.30M |
| August 12, 2026 | 185.09M |
| August 11, 2026 | 162.88M |
| August 10, 2026 | 226.32M |
| August 07, 2026 | 219.98M |
| August 06, 2026 | 221.24M |
| August 05, 2026 | 181.92M |
| August 04, 2026 | 183.82M |
| Date | Value |
|---|---|
| August 03, 2026 | 176.21M |
| July 31, 2026 | 151.47M |
| July 30, 2026 | 165.42M |
| July 29, 2026 | 168.59M |
| July 28, 2026 | 167.96M |
| July 27, 2026 | 167.96M |
| July 24, 2026 | 148.93M |
| July 23, 2026 | 153.37M |
| July 22, 2026 | 143.85M |
| July 21, 2026 | 124.82M |
| July 20, 2026 | 126.09M |
| July 17, 2026 | 133.07M |
| July 16, 2026 | 124.82M |
| July 15, 2026 | 137.51M |
| July 14, 2026 | 128.63M |
| July 13, 2026 | 138.15M |
| July 10, 2026 | 152.74M |
| July 09, 2026 | 150.83M |
| July 08, 2026 | 154.00M |
| July 07, 2026 | 178.11M |
| July 06, 2026 | 139.41M |
| July 02, 2026 | 150.20M |
| July 01, 2026 | 164.15M |
| June 30, 2026 | 174.30M |
| June 29, 2026 | 155.46M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.865B |
| Alnylam Pharmaceuticals, Inc. | 34.46B |
| Anika Therapeutics, Inc. | 268.42M |
| Savara, Inc. | 993.23M |
| Vericel Corp. | 1.932B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -25.35M |
| Total Expenses (Quarterly) | 25.35M |
| EPS Diluted (Quarterly) | -0.3961 |
| Earnings Yield | -41.52% |
| Normalized Earnings Yield | -41.52 |